1. The voluntary error reporting system for vaccines which has been established by the Institute for Safe Medication Practices (ISMP) is known as:
A. VAERS
B. VERP
C. VICP
D. NCVIA
2. Which one of the following vaccines would be deferred in patients who have an unstable seizure disorder until the disorder is well controlled?
A. Influenza
B. MMR
C. Tdap
D. Varicella
3. Which of the following is indicated for use during pregnancy?
A. Tdap
B. MMR
C. Varicella
D. Varicella Zoster
4. Two live vaccines being administered to the same patient must be administered either on the same day, or must be separated by ____________ to reduce the possibility of interfering with the body's immune response.
A. 7 days
B. 28 days
C. 60 days
D. 180 days
5. When a vaccine is inadvertently stored outside of the recommended temperature range, the vaccine should be:
A. Discarded
B. Returned to appropriate storage, allowed to reach the desired temperature, then used
C. Placed in a bag or bin, refrigerated, separated from remaining vaccine supply, and marked “Do Not Use,” and the vaccine manufacturer contacted.
D. Returned to the manufacturer for replacement or refund
6. HRSA and researchers recommend steps prevent SIRVA; vaccine administrators should:
A. Bringing vaccines to room temperature prior to administration
B. Always using a 1.5 inch needle for any patient aged 19 years or older
C. Ensuring that both the administrator and the recipient are seated when injecting
D. Administer vaccine only in the upper third of the deltoid
7. If a patient had a localized, dermatologic reaction to neomycin in the past, the patient:
A. Should receive desensitization therapy prior to getting an MMR vaccine
B. Should never receive MMR vaccine
C. Should be referred to the county health department for further evaluation
D. Should receive MMR vaccine if it is indicated
8. According to the IDSA, a patient receiving tumor necrosis factor alpha immunobiologic therapy:
A. Is considered highly immunocompromised and should not receive varicella zoster live vaccine
B. Is considered only slightly immunocompromised and can receive varicella zoster live vaccine as long as the patient is monitored for 15 minutes following vaccine administration
C. Can receive varicella zoster live vaccine only if the immunobiologic agent is discontinued for at least 1 week and not restarted until at least 2 weeks after receiving the vaccine
D. Can proceed with immunization with varicella zoster live vaccine without concern since TNF-alpha drugs are not immunocompromising
9. Vaccines which are to be stored at a frozen temperature should be ideally stored in a stand-alone freezer unit at what temperature (in degrees Celsius)?
A. 2 to 8
B. 5
C. –50 to –15
D. 0 to 32
10. Which of the following represents the dose equivalent of prednisone which is considered immunosuppressive when taken for 2 weeks or longer, indicating that the patient should not receive a live-attenuated vaccine:
A. 5 mg per day
B. 10 mg per day
C. 15 mg per day
D. 20 mg per day
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20
